文献速递糖尿病

抑郁与1型糖尿病糖尿病肾病进展相关

Depression Is Associated With Progression of Diabetic Nephropathy in Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2020-11-11

基于芬兰糖尿病肾病研究3730例基线无终末期肾病的1型糖尿病患者,平均随访9.6年,18.4%肾功能恶化。基线前抑郁诊断与抗抑郁药购买分别与肾病进展风险增加53%和32%相关,随访期抑郁诊断亦与进展风险增加32%相关。

要点

  • 抑郁诊断与抗抑郁药购买均与1型糖尿病肾病进展风险升高相关
  • 随访期抑郁诊断仍与肾病进展风险增加32%相关
  • 抑郁症状仅在年龄≤36.5岁者中额外预测肾病进展

核心结论

  • 已诊断抑郁和抗抑郁药购买与1型糖尿病中糖尿病肾病的进展相关。
  • 抑郁的成功治疗能否降低肾病进展风险尚待确定。

研究设计与样本

  • 芬兰糖尿病肾病研究队列,纳入基线无终末期肾病的3730例参与者。
  • 抑郁通过三种方式评估:芬兰医疗保健登记诊断、药物处方登记抗抑郁药购买、贝克抑郁量表(BDI)症状评分。
  • 按尿白蛋白排泄率(AER)分为正常、微量白蛋白尿和大量白蛋白尿,随访观察肾病进展。

主要发现

  • 平均随访9.6年,18.4%的参与者肾脏状态恶化。
  • 基线前抑郁诊断与肾病进展风险增加53%相关,基线前抗抑郁药购买与风险增加32%相关。
  • 随访期评估的抑郁诊断仍与疾病进展风险增加32%相关。
  • BDI抑郁症状与进展无关联,但抗抑郁药购买总数轻度降低风险(HR 0.989[95%CI 0.982-0.997],P=0.008)。
  • 按中位年龄分组后结果与全组一致,但抑郁症状仅在年龄≤36.5岁者中额外预测进展。

关键数值与推荐

  • 随访期肾脏状态恶化者占18.4%。
  • 基线前抑郁诊断:肾病进展风险增加53%。
  • 基线前抗抑郁药购买:肾病进展风险增加32%。
  • 随访期抑郁诊断:肾病进展风险增加32%。
  • 抗抑郁药购买总数与进展风险:HR 0.989(95%CI 0.982-0.997),P=0.008。

临床怎么用

  • 对1型糖尿病患者应关注抑郁诊断与抗抑郁药使用情况,作为肾病进展风险分层参考。
  • 年轻(≤36.5岁)1型糖尿病患者的抑郁症状可能提示肾病进展风险,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the relationship between depression and diabetic nephropathy progression in type 1 diabetes. RESEARCH DESIGN AND METHODS: Data from 3,730 participants without end-stage renal disease (ESRD) at baseline, participating in the Finnish Diabetic Nephropathy Study, were included. Depression was assessed in three ways. Depression diagnoses were obtained from the Finnish Care Register for Health Care. Antidepressant agent purchase data were obtained from the Drug Prescription Register. Symptoms of depression were assessed using the Beck Depression Inventory (BDI). Based on their urinary albumin excretion rate (AER), participants were classified as those with normal AER, microalbuminuria, and macroalbuminuria. Progression from normal AER to microalbuminuria, macroalbuminuria, or ESRD; from microalbuminuria to macroalbuminuria or ESRD; or from macroalbuminuria to ESRD, during the follow-up period, was investigated. RESULTS: Over a mean follow-up period of 9.6 years, renal status deteriorated in 18.4% of the participants. Diagnosed depression and antidepressant purchases before baseline were associated with 53% and 32% increased risk of diabetic nephropathy progression, respectively. Diagnosed depression assessed during follow-up remained associated with increased risk of disease progression (32%). BDI-derived symptoms of depression showed no association with the progression, but the total number of antidepressant purchases modestly reduced the risk (hazard ratio 0.989 [95% CI 0.982-0.997]), P = 0.008). With the sample divided based on median age, the observations followed those seen in the whole group. However, symptoms of depression additionally predicted progression in those age ≤36.5 years. CONCLUSIONS: Diagnosed depression and antidepressant purchases are associated with the progression of diabetic nephropathy in type 1 diabetes. Whether successful treatment of depression reduces the risk needs to be determined.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ahola AJ, Harjutsalo V, Forsblom C, et al. Depression Is Associated With Progression of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care. 2020. PMID: 33177173. doi:10.2337/dc20-0493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。